Year ended December 31, CASH FLOWS PROVIDED BY OPERATING ACTIVITIES Earnings (loss) from continuing operations $ (52.5) $ 64.0 $170.0 Non-cash items included in earnings (loss) from continuing operations:  Cumulative effect of accounting change for derivative instruments – – 1.7 In-process research and development  458.0 – 40.0 Depreciation and amortization 59.6 45.0 53.0 Amortization of original issue discount 6.9 11.0 10.1 Write-off of deferred convertible debt issue costs 0.9 8.0 – Deferred income taxes (benefit) (61.6) (13.8) 14.1 Loss on investments – 30.2 4.5 Loss (gain) on sale/abandonment of assets 3.7 (5.7) 0.8 Unrealized loss (gain) on derivatives 0.3 1.7 (4.2) Gain on divestiture of pharmaceutical products – – (2.0) Expense of compensation plans 10.3 10.3 7.1 Minority interest 0.8 0.7 0.6 Restructuring charge (reversal) and asset write-offs, net (0.4) 62.4 (1.7) Changes in assets and liabilities: Trade receivables 12.5 (49.5) (2.7) Inventories (3.3) (16.7) (7.7) Other current assets (7.6) 9.1 (18.1) Accounts payable (4.4) 4.1 9.2 Accrued expenses and other liabilities 46.0 13.6 (9.8) Income taxes 15.3 (43.7) 42.4 Other non-current assets (49.2) (83.1) (15.3) Net cash provided by continuing operations 435.3 47.6 292.0 CASH FLOWS FROM INVESTING ACTIVITIES Additions to property, plant and equipment (109.6) (78.8) (84.1) Proceeds from sale of property, plant and equipment  – 6.9 4.6 Acquisitions, net of cash acquired (469.5) – (70.2) Other, net (15.8) (7.7) (17.1) Net cash used in investing activities (594.9) (79.6) (166.8) In millions 2003 2002 2001 condensed consolidated statements of cash flows